Wilhelmina Childrens Hospital

The medical center is at the forefront of research in Cystic Fibrosis, focusing on the long-term safety and tolerability of innovative therapies. The center's work in this area aims to improve the quality of life for patients by exploring new treatment combinations.

• Long-term safety of elexacaftor/tezacaftor/ivacaftor
• Therapeutic advancements in non-F508del mutations

Through its research, the center contributes significantly to the understanding and management of Cystic Fibrosis, offering hope for more effective treatments.

Specializing in GRIN-related Disorder, the center conducts pivotal studies to assess the safety and pharmacokinetics of novel treatments in pediatric patients. This research is crucial for developing therapies that address both seizures and behavioral symptoms.

• Safety and tolerability of radiprodil
• Pharmacokinetics in pediatric populations

The center's efforts in this field are instrumental in paving the way for new therapeutic options for children affected by GRIN-related Disorder.

Focusing on Juvenile Idiopathic Arthritis, the center evaluates the efficacy of treatments like ixekizumab and apremilast in children. These studies aim to improve outcomes for subtypes such as Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis.

• Efficacy of ixekizumab in JIA subtypes
• Apremilast in Juvenile Psoriatic Arthritis

By advancing research in Juvenile Idiopathic Arthritis, the center is committed to enhancing therapeutic strategies for young patients.

The center is a leader in Inflammatory Bowel Disease research, particularly in pediatric Crohn's Disease. It focuses on optimizing treatment regimens to maintain therapeutic drug levels without escalation.

• Pharmacokinetics of infliximab
• Optimizing treatment strategies

Through its research, the center aims to refine treatment protocols for Inflammatory Bowel Disease, improving patient outcomes.

In the realm of Alagille Syndrome, the center investigates the long-term effects of odevixibat, focusing on its impact on pruritus and overall safety in young patients.

• Sustained effect of odevixibat on pruritus
• Safety in infants

The center's research in Alagille Syndrome is vital for developing effective management strategies for this rare condition.

Specializing in Macrophage Activation Syndrome, the center evaluates the efficacy of emapalumab in both pediatric and adult patients, addressing conditions like systemic juvenile idiopathic arthritis and systemic lupus erythematosus.

• Efficacy of emapalumab in MAS
• Therapeutic approaches for sJIA and SLE

Research in Macrophage Activation Syndrome at the center is crucial for advancing treatment options for these complex conditions.

The center's research in Systemic Juvenile Idiopathic Arthritis focuses on optimizing treatment protocols using biomarkers to reduce the need for medication while maintaining disease inactivity.

• Use of IL-18 biomarker in treatment
• Reducing medication dependency

By exploring innovative approaches in Systemic Juvenile Idiopathic Arthritis, the center aims to improve patient care and treatment efficiency.